Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Infinex launches Sonar pre-sale round, distributing 5% of INX tokens before January TGE

Infinex launches Sonar pre-sale round, distributing 5% of INX tokens before January TGE

ChaincatcherChaincatcher2025/11/27 14:17
Show original

According to ChainCatcher, citing The Block, the crypto super app Infinex has announced that it will launch a presale round for the INX token via the Sonar platform, planning to sell 5% of the total supply at a valuation of $300 million, aiming to raise $15 million.

This distribution is open to supporters who participated in Patron NFT last year, with a lottery channel available for regular users. The sold tokens will be locked for one year, with an option to pay for early unlocking. INX is scheduled to be officially generated and listed for circulation in January 2026. The platform integrates wallet, trading, prediction, cross-chain, and other functions, aiming to become the next-generation Web3 gateway.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.